Hormones

Ability to drive, parathyroid hormone [2] ---> SmPC of [2] of EMA

Patients with disturbances in cognition or attention should be advised to refrain from driving or using machines until symptoms have subsided.

Acarbose, thyroid hormones

The combined active ingredient with acarbose may cause hyperglycaemia, what may attenuate the acarbose effects. Monitorization of the blood-sugar concentration is recommended

Acenocoumarol [1], thyroid hormones ---> SmPC of [1] of eMC

The co-administration may enhance the anticoagulant effect of acenocoumarol and increase the bleeding risk

Adrenaline, thyroid hormones

The effects of adrenaline may be potentiated by thyroid hormones

Ajmaline, hormones

The co-administration of ajmaline with hormones increases the frequency of long-lasting cholestasis

Alendronic acid, parathyroid hormone [2] ---> SmPC of [2] of EMA

Co-administration of alendronic acid and Natpar may lead to a reduction in the calcium sparing effect, which can interfere with the normalisation of serum calcium.

Amezinium, thyroid hormones

Enhancement of sympathomimetic effect

Aminophylline, thyroid hormones

Thyroid hormones may decrease aminophylline clearance resulting in increased plasma theophylline concentrations and the potential for increased toxicity

Amitriptyline, thyroid hormones

Thyroid hormone may enhance effects of amitriptyline

Anastrozole [1], growth hormone ---> SmPC of [1] of eMC

Anastrozole should not be used in boys/girls with growth hormone deficiency in addition to growth hormone treatment.

Antidiabetics, thyroid hormones

Increased or decreased hypoglycemia

Asfotase alfa [1], parathyroid hormone ---> SmPC of [1] of EMA

It is recommended that serum parathyroid hormone and calcium be monitored in patients treated with asfotase alfa.

Biphosphonates, parathyroid hormone [2] ---> SmPC of [2] of EMA

Concomitant use of Natpar with bisphosphonates is not recommended.

Breast-feeding, parathyroid hormone [2] ---> SmPC of [2] of EMA

A decision must be made whether to discontinue breast-feeding or to discontinue therapy with Natpar, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman

Breast-feeding, thyroid hormones

The treatment with thyroid hormones should not be discontinued during breast-feeding

Caffeine, thyroid hormones

Increased tachycardic effect

Carbamazepine, thyroid hormones

Carbamazepine, enzymatic inductor, increases the metabolism of the thyroid hormone and may also displace the thyroid hormone from its plasma protein binding sites

Cholestyramine, thyroid hormones

Cholestyramine may delay/decrease the absorption of the co-administered medicament. This medicine should be administered 1 hour before or 4-6 hours after colestyramine

Clomipramine [1], thyroid hormones ---> SmPC of [1] of eMC

Caution is indicated during concomitant treatment of clomipramine with thyroid preparations since aggravation of unwanted cardiac effects may occur.

Colestilan [1], steroid hormones ---> SmPC of [1] of EMA

Reduced bioavailability of other medicinal products been reported. You should the other medicine up to 1 hour prior to or 3 hours following colestilan

Cytochrome P450, parathyroid hormone [2] ---> SmPC of [2] of EMA

Natpar is a protein that is not metabolised by and does not inhibit hepatic microsomal drug-metabolising enzymes (e.g., cytochrome P450 isoenzymes).

Digital glycosides, parathyroid hormone [2] ---> SmPC of [2] of EMA

The combined use of parathyroid hormone and digital glycosides may predispose to digitalis toxicity if hypercalcemia develops.

Digitoxin, parathyroid hormone [2] ---> SmPC of [2] of EMA

The combined use of parathyroid hormone and digital glycosides may predispose to digitalis toxicity if hypercalcemia develops.

Digoxin, parathyroid hormone [2] ---> SmPC of [2] of EMA

The combined use of parathyroid hormone and digital glycosides may predispose to digitalis toxicity if hypercalcemia develops.

Dihydrotachysterol, thyroid hormones

Thyroid replacement therapy may increase clearance of dihydrotachysterol

Epinephrine, thyroid hormones

The effects of adrenaline may be potentiated by thyroid hormones

Esketamine [1], thyroid hormones ---> SmPC of [1] of EMA

Blood pressure should be closely monitored when Spravato is used concomitantly with psychostimulants or other medicinal products that may increase blood pressure

Esketamine, thyroid hormones

The co-administration may cause arterial hypertension and tachycardia

Etilefrine, thyroid hormones

The co-administration may increase the effect of etilefrine

Fibrates, thyroid hormones

Increased plasma levels of thyroid hormone

Fludrocortisone, growth hormone

The growth-promoting effect may be inhibited.

Furosemide, thyroid hormones

Increased plasma levels of thyroid hormone

Glibenclamide, male sex hormones

The co-administration may enhance the hypoglycemic effect

Glibenclamide, thyroid hormones

The co-administration may weaken the hypoglycemic effect

Glimepiride [1], male sex hormones ---> SmPC of [1] of eMC

Potentiation of the blood-sugar-lowering effect and possible hypoglycaemia

Glimepiride [1], thyroid hormones ---> SmPC of [1] of eMC

Weakening of the blood-glucose-lowering effect and possible hyperglycaemia

Gliquidone, thyroid hormones

Hyperglycemic reactions may occur as expression of weakening effect of gliquidone with gliquidone is co-administered with thyroid hormones

Glucocorticoids, growth hormone

The growth-promoting effect may be inhibited

Growth hormone, human insulin [2] ---> SmPC of [2] of EMA

Possible increasing in patient's insulin requirement

Growth hormone, insulin

Possible increase of the insulin requirements

Growth hormone, insulin aspart [2] ---> SmPC of [2] of EMA

Possible increase of the insulin requirements

Growth hormone, insulin degludec [2] ---> SmPC of [2] of EMA

Possible increase of the insulin requirements

Growth hormone, insulin degludec/insulin aspart [2] ---> SmPC of [2] of EMA

Possible increase of the insulin requirements

Growth hormone, insulin degludec/liraglutide [2] ---> SmPC of [2] of EMA

Possible increase of the Xultophy requirements

Growth hormone, insulin detemir [2] ---> SmPC of [2] of EMA

Possible increase of the insulin requirements

Growth hormone, insulin glargin [2] ---> SmPC of [2] of EMA

Reduced blood-glucose-lowering effect

Growth hormone, lonapegsomatropin [2] ---> SmPC of [2] of EMA

Because growth hormone increases the extrathyroidal conversion of T4 to T3, adjustment of thyroid hormone replacement therapy may be necessary

Growth hormone, macimorelin [2] ---> SmPC of [2] of EMA

The combination may impact the accuracy of the diagnostic test. Concomitant use with macimorelin is to be avoided. Growth hormone medicinal products should be discontinued at least 1 month before administering macimorelin.

Growth hormone, somatorelin [2] ---> SmPC of [2] of eMC

Concomitant use of somatorelin and substances influencing the release of growth hormone should be avoided.

Growth hormone, somatrogon [2] ---> SmPC of [2] of EMA

Treatment with daily growth hormone may unmask previously undiagnosed or subclinical central hypothyroidism.

Growth hormone, triamcinolone acetonide

The growth-promoting effect may be inhibited.

Growth hormone, triamcinolone [2] ---> SmPC of [2] of eMC

The growth-promoting effect may be inhibited.

Hormones, prajmalium

The co-administration of prajmalium with hormones (oral contraceptives) increases the frequency of long-lasting cholestasis

Hormones, somapacitan [2] ---> SmPC of [2] of EMA

The metabolic effects of somapacitan can also be influenced by concomitant therapy with other hormones, e.g. testosterone and thyroid hormones

Hormones, tamoxifen [2] ---> SmPC of [2] of eMC

Hormone preparations, particularly oestrogens (e.g. oral contraceptives) should not be combined with tamoxifen because a mutual decrease in effect is possible.

Human insulin [1], thyroid hormones ---> SmPC of [1] of EMA

Possible increasing in patient's insulin requirement

Imipramine, thyroid hormones

Thyroid hormone may enhance effects of imipramine

Insulin aspart [1], thyroid hormones ---> SmPC of [1] of EMA

Possible increase of the insulin requirements

Insulin degludec [1], thyroid hormones ---> SmPC of [1] of EMA

Possible increase of the insulin requirements

Insulin degludec/insulin aspart [1], thyroid hormones ---> SmPC of [1] of EMA

Possible increase of the insulin requirements

Insulin degludec/liraglutide [1], thyroid hormones ---> SmPC of [1] of EMA

Possible increase of the Xultophy requirements

Insulin detemir [1], thyroid hormones ---> SmPC of [1] of EMA

Possible increase of the insulin requirements

Insulin glargin [1], thyroid hormones ---> SmPC of [1] of EMA

Reduced blood-glucose-lowering effect

Insulin glargine/lixisenatide [1], thyroid hormones ---> SmPC of [1] of EMA

This substance may reduce the blood-glucose-lowering effect.

Insulin glulisin [1], thyroid hormones ---> SmPC of [1] of EMA

Possible decrease in blood-glucose-lowering activity

Insulin lispro [1], thyroid hormones ---> SmPC of [1] of EMA

Insulin requirements may be increased by medicinal products with hyperglycaemic activity

Insulin, thyroid hormones

The co-administration may decrease the effect of insulin

Ketamine [1], thyroid hormones ---> SmPC of [1] of eMC

Patients taking thyroid hormones have an increased risk of developing hypertension and tachycardia when given ketamine.

Lithium, parathyroid hormone [2] ---> SmPC of [2] of EMA

For any drug that affects serum calcium levels (e.g., lithium, thiazides), patients' serum calcium levels should be monitored.

Lofepramine, thyroid hormones

Unwanted cardiac effects may be aggravated during concomitant treatment of lofepramine with thyroid hormone therapy

Maprotiline, thyroid hormones

Possible enhancement of cardiovascular adverse reactions

Mephenytoin, thyroid hormones

Increased hydantoin plasma levels

Metformin, thyroid hormones

Decreased hypoglycemic effect

Metildigoxin, thyroid hormones

Effect weakening of metildigoxin

Midodrine, thyroid hormones

The co-administration may cause pronounced hypertension. The combination should be avoided

Nelfinavir, steroid hormones ---> SmPC of [estradiol] of eMC

Ritonavir and nelfinavir, although known as strong inhibitors, by contrast exhibit inducing properties when used concomitantly with steroid hormones.

Noradrenaline, thyroid hormones ---> SmPC of [norepinephrine] of eMC

Thyroid hormones may increase the noradrenaline effects

Norepinephrine, thyroid hormones

Thyroid hormones may increase the noradrenaline effects

Nortriptyline [1], thyroid hormones ---> SmPC of [1] of eMC

Great care is necessary if nortriptyline is administered to patients receiving thyroid medication, since cardiac arrhythmias may develop.

Oral anticoagulants, thyroid hormones

The co-administration may enhance the anticoagulant effect and increase the bleeding risk

Oral antidiabetics, thyroid hormones

The co-administration may decrease the effect of antidiabetic agent

Parathyroid hormone [1], pregnancy ---> SmPC of [1] of EMA

A decision must be made whether to initiate or discontinue treatment with Natpar during pregnancy taking into account the known risks of therapy versus the benefit for the woman.

Parathyroid hormone [1], thiazides ---> SmPC of [1] of EMA

For any drug that affects serum calcium levels (e.g., lithium, thiazides), patients' serum calcium levels should be monitored.

Phenindione [1], thyroid hormones ---> SmPC of [1] of eMC

Thyroid compounds potentiate the effect of phenindione

Phenobarbital [1], thyroid hormones ---> SmPC of [1] of eMC

Phenobarbital increases the rate of metabolism reducing serum concentrations of thyroid hormones, it may increase requirements for thyroid hormones in hypothyroidism.

Phenprocoumon, thyroid hormones

Enhancement of phenprocoumon effect and increased bleeding risk with the concomitant administration of thyroid hormones

Phenylbutazone, thyroid hormones

Phenylbutazone can displace the thyroid hormone from its plasma protein binding and increase its plasma levels

Phenytoin, thyroid hormones

Phenytoin, enzymatic inductor, increases the metabolism of thyroid hormone and can displace thyroid hormone from plasma proteins

Piracetam [1], thyroid hormones ---> SmPC of [1] of eMC

Confusion, irritability and sleep disorder have been reported during concomitant treatment with thyroid extract (T3 + T4).

Pregnancy, thyroid hormones

The treatment with thyroid hormones should not be discontinued during the pregnancy

Protirelin, thyroid hormones

Reduction of TSH-increase

Pseudoephedrine, thyroid hormones

Concomitant use of pseudoephedrine with thyroid hormones may increase the effects of pseudoephedrine

Repaglinide [1], thyroid hormones ---> SmPC of [1] of EMA

Thyroid hormones may reduce the hypoglycaemic effect of repaglinide

Rifampicin [1], thyroid hormones ---> SmPC of [1] of eMC

Rifampicin has enzyme induction properties that can enhance the metabolism of endogenous substrates including adrenal hormones, thyroid hormones and vitamin D.

Ritonavir, steroid hormones ---> SmPC of [estradiol] of eMC

Ritonavir and nelfinavir, although known as strong inhibitors, by contrast exhibit inducing properties when used concomitantly with steroid hormones.

Salicylates, thyroid hormones

Increased plasma levels of thyroid hormone

Sodium iodide, thyroid hormones

The withdrawal period prior to administration of sodium [131I]iodine is 2-6 weeks

Somapacitan [1], thyroid hormones ---> SmPC of [1] of EMA

The metabolic effects of somapacitan can also be influenced by concomitant therapy with other hormones, e.g. testosterone and thyroid hormones

Somatropin [1], thyroid hormones ---> SmPC of [1] of EMA

Growth hormone increases the extrathyroidal conversion of thyroxin (T4) to triiodothyronine (T3) and may unmask central hypothyroidism. Thyroxine replacement therapy may therefore need to be initiated or adjusted.

Sulfonylureas, thyroid hormones

Weakening of the blood-glucose-lowering effect and, thus raised blood glucose levels may occur

Thyroid hormones, tricyclic antidepressant ---> SmPC of [clomipramine] of eMC

Caution is indicated during concomitant treatment with thyroid preparations and tricyclic antidepressant, since aggravation of unwanted cardiac effects may occur.

Thyroid hormones, vildagliptin [2] ---> SmPC of [2] of EMA

As with other oral antidiabetic medicinal products the hypoglycaemic effect of vildagliptin may be reduced by certain active substances, including thiazides, corticosteroids, thyroid products and sympathomimetics.

Thyroid hormones, vildagliptin/metformin [2] ---> SmPC of [2] of EMA

As with other oral antidiabetic medicinal products the hypoglycaemic effect of vildagliptin may be reduced by certain active substances, including thiazides, corticosteroids, thyroid products and sympathomimetics.